Welcome to our dedicated page for Halberd news (Ticker: HALB), a resource for investors and traders seeking the latest updates and insights on Halberd stock.
Halberd Corporation (HALB) is an innovative biopharmaceutical company developing targeted therapies for PTSD, traumatic brain injury, and related mental health conditions through patented drug formulations and wearable monitoring technologies. This news hub provides investors and researchers with timely updates on the company's clinical trials, intellectual property developments, and strategic partnerships.
Access authoritative information about HALB's progress in mental health treatment innovation, including updates on its LDN+ and Tri-Ax nasal spray therapies. The repository consolidates press releases related to CRADA clinical trials, technology integrations with partners like Athena GTX, and patent filings that underpin the company's valuation.
Key content categories include regulatory milestones, research collaborations with military healthcare providers, and advancements in combined pharmaceutical/digital health solutions. All materials maintain compliance with OTC Market disclosure standards while emphasizing HALB's unique position at the intersection of biopharma and wearable diagnostics.
Bookmark this page for streamlined tracking of HALB's progress in addressing critical mental health challenges through evidence-based therapeutic innovation. Check regularly for verified updates that reflect the company's commitment to advancing both patient care and shareholder value.
Halberd Corporation (OTC PINK: HALB) has filed an International Patent Cooperation Treaty (PCT) application for its invention titled Covid-19 Inflammatory Cytokine Storm Treatment. This application expands its patent protection across over 150 countries. The treatment aims to tackle Covid-19 and other diseases via a patented extracorporeal process, with current experiments being conducted in collaboration with GreenBioAZ and Youngstown State University. Halberd also holds exclusive rights to multiple related technologies and has filed various provisional patent applications concerning Covid-19 treatments.
Halberd Corporation (OTC PINK: HALB) reported significant progress in Q1 2021, showcasing a remarkable 17,500% stock appreciation over the past year and a 280% increase in the first quarter alone. Key accomplishments include developing patent-pending technologies for SARS-CoV-2, such as a novel fluorescent antibody and multiple antibodies targeting the Spike Protein. The company secured a $2 million funding commitment and maintained active investor communications. Goals for Q2 include enhancing corporate listings and initiating testing on various pathogens, maintaining momentum in innovation and shareholder value.
Halberd Corporation (OTC PINK:HALB) has achieved a significant milestone by successfully conjugating metallic nanoparticles with its patent-pending SARS-CoV-2 antibody, maintaining its neutralizing properties. This development is crucial for utilizing radio frequency (RF) energy in disease eradication. Additionally, the company has shown efficacy in E. Coli antibodies, broadening its application scope. Chairman William A. Hartman emphasized the swift intellectual property protection and forthcoming lab tests with university partners to assess RF's effectiveness against disease antigens.
Halberd Corporation (OTC PINK:HALB) has compiled various peer-reviewed medical articles supporting the selection of nutraceuticals for its VITA-SHIELD-MAX Immune Booster. CEO William A. Hartman emphasized the consensus on ingredients to enhance health and well-being. This compilation will be shared with sales teams and medical facilities to raise awareness. Halberd is debt-free and holds exclusive rights to multiple patent-pending COVID-19 treatments, indicating a strong position in the healthcare market.
Halberd Corporation (OTC PINK:HALB) has filed a PCT application for its invention titled Method for Treating and Curing Covid-19 Infection. This filing allows patent protection in over 150 countries, enhancing its global reach. CEO William A. Hartman expressed confidence in their technology, which includes treatments using radiofrequency and laser methodologies. The initial U.S. provisional patent was filed on March 16, 2020. Halberd Corporation holds exclusive rights to various COVID-19 treatment patents and is committed to advancing its research despite uncertainties surrounding the pandemic.
Halberd Corporation (OTC PINK:HALB) announced a partnership with a leading nutraceutical manufacturer for the initial production of its VITA-SHIELD-MAX Immune Booster. This proprietary formulation aims to enhance natural immunity, developed after extensive research and consultations with medical professionals. CEO William A. Hartman expressed confidence that the product, supported by third-party research materials, will appeal to large retailers. The company maintains exclusive rights to numerous COVID-19 treatment technologies, emphasizing its compliance with OTC reporting requirements.
Halberd Corporation (OTC PINK:HALB) has filed for trademark protection for VITA-SHIELD-MAX, a proprietary blend of nutraceuticals aimed at enhancing immunity and overall health. CEO William A. Hartman expressed optimism about the product's launch, expected in Q2 2021, emphasizing its role in boosting nutrient levels to combat health issues. The company assures compliance with OTC Market standards, holding exclusive rights to multiple COVID-19 treatment patents. However, the ongoing pandemic's impact on operations remains uncertain.
Halberd Corporation (OTC PINK:HALB) recently shared advances in antibody development during an interview on The Stock Day Podcast with CEO William A. Hartman. A new antibody shows 20 times greater neutralization affinity against SARS-CoV-2, with plans for FDA approval. The company is also working with GreenBioAz on radio-frequency treatments to combat diseases, including initial tests on E. Coli in distilled water. Additionally, Halberd's upcoming vitamin cocktail aims to enhance immunity, with anticipated revenue generation by Q2 or Q3 2021.
Halberd Corp. has announced the development of a new monoclonal antibody with over 20 times greater neutralizing affinity against the SARS-COV-2 Spike protein. This advancement positions Halberd's antibody among the most effective against COVID-19. The company's CEO expressed optimism regarding potential partnerships with biotech firms to enhance treatment effectiveness. Additionally, Halberd is progressing in their immune booster vitamin development while also working on a patented extracorporeal radio frequency project designed to eliminate various diseases.
Halberd Corp (OTC PINK:HALB) has partnered with GreenBioAZ, Inc. for laboratory testing of its patent pending Radio Frequency (RF) technology aimed at eliminating infectious disease pathogens like SARS-CoV-2. The process involves using an Antibody-Metallic Moiety Conjugate to target pathogens, converting electromagnetic waves into thermal energy to eradicate viral particles without harming healthy cells. Successful trials could pave the way for future treatments. Halberd emphasizes that these tests represent critical advancements towards developing commercially viable therapies.
FAQ
What is the current stock price of Halberd (HALB)?
What is the market cap of Halberd (HALB)?
